^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | setidegrasib (ASP3082) (KRAS G12D degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
Excerpt:
......
Trial ID:
Source:
Title:
5735 - Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Published date:
03/15/2023
Excerpt:
ASP3082 exhibited potent antitumor activities in not only PDAC but also CRC and non-small cell lung cancer KRAS G12D-mutated mouse models. These studies demonstrated that ASP3082 induced degradation of KRAS G12D protein, inhibition of KRAS downstream molecules, and an apoptotic response to show dose-dependent antitumor activity in multiple KRAS G12D-mutated cancer models.